Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 01, 2026
TickeronGET DAILY SIGNALS
UnitedHealth Group (UNH): Can Shares Reach the $490 Target?

UnitedHealth Group (UNH): Can Shares Reach the $490 Target?

Key Takeaways

  • The central $490 stock price target is the arithmetic mean of nine verified, current analyst price targets reviewed for this article, rounded from a calculated average of roughly $493.
  • At the latest verified close near $410.91, reaching $490 implies roughly 19% upside from current levels.
  • Individual analyst price targets range from a low of $438 (Deutsche Bank) to a high of $531 (Morgan Stanley), reflecting a meaningful spread in views.
  • The strongest supports are better-than-expected third-quarter results, a third full-year guidance increase, and improving medical cost trends.
  • The biggest risks are Medicare Advantage regulation, residual Department of Justice scrutiny, and a valuation that has already re-rated higher.
  • Readers can find more on Major News, Today's Price Move, Forecast, and Earnings on dedicated pages.
  • Explore Trending AI Robots to see how AI-driven strategies are monitoring opportunities across the market.

Analyst Price Targets and Consensus View

This analysis draws from nine current, individually verified analyst price targets published in mid-to-late October 2026, following UnitedHealth's third-quarter earnings report. The targets range from Deutsche Bank's $438 to Morgan Stanley's $531, with most other firms clustered between $487 and $524. The simple arithmetic mean of these nine targets is approximately $493, which rounds to the $490 central target used throughout this article.

Views differ more than the headline average suggests. Morgan Stanley ($531), J.P. Morgan ($524), Goldman Sachs ($506), Piper Sandler ($504), Mizuho ($500), and RBC Capital ($498) sit at or above $500, while Wells Fargo ($487), Jefferies ($453), and Deutsche Bank ($438) are more restrained. Notably, some firms trimmed targets even while keeping buy ratings — Wells Fargo lowered its target to $487 from $526 — while Deutsche Bank carries a Hold rating, arguing the near-term valuation already prices in much of the expected recovery. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Bullish analysts point to a multi-year, multi-segment margin recovery and durable double-digit earnings growth, while the more cautious voices focus on valuation and residual policy uncertainty. The analyst consensus on UNH is best described as moderately bullish but not uniform.

Current Market Position and Path Toward the Target

At the latest verified close of $410.91, UNH trades roughly 19% below the $490 central target — a substantial, though not extreme, move. The shares have already climbed far off their 52-week low of $255.97 and now sit within reach of the 52-week high near $461.62.

The path toward the target runs through improving fundamentals. After a period defined by elevated Medicare Advantage medical costs and a Department of Justice investigation, UnitedHealth reported third-quarter adjusted EPS of $4.69, well above consensus near $4.14, on a better-than-expected MLR. Management raised 2026 adjusted EPS guidance for the third time this year, with the floor now implying roughly 25% year-over-year growth, and described OptumHealth's outperformance as durable.

What Could Support a Move Toward the Target

  • Earnings momentum. A clean third-quarter beat and repeated guidance increases give analysts a credible basis for higher targets.
  • Improving cost trends. A better MLR and management's pricing discipline in Medicare Advantage support the margin-recovery thesis.
  • Optum and value-based care. Continued strength in the higher-growth Optum business underpins the long-term growth argument.
  • Positive analyst revisions. Several firms raised targets in October, with the central target now well above current trading levels.

What Could Prevent the Target From Being Reached

  • Valuation. After a sharp rally, some analysts argue the forward multiple already discounts the expected 2027–2028 earnings recovery.
  • Regulatory risk. Medicare Advantage rate and policy decisions can quickly reshape margin assumptions across managed care.
  • Legal scrutiny. The Department of Justice investigation into Medicare billing practices remains an unresolved overhang.
  • Diverging targets. The wide $438-to-$531 range signals genuine disagreement about how durable the margin recovery will be.

Technical Levels and Market Structure

The 52-week high near $461.62 is the nearest major technical hurdle; a sustained move above it would open a path toward the $490 area. On the downside, the psychological $400 level and the prior consolidation zone near $390 represent support areas to watch. UNH's longer-term structure has shifted from a deep decline to a recovery, but the stock remains below its historical highs.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a research horizon of roughly 12 months, though individual firms vary. Investors should monitor quarterly earnings and MLR trends, any further guidance revisions, Medicare Advantage rate notices, and developments in the Department of Justice investigation. Changes in analyst price targets and ratings will also signal whether the recovery thesis is gaining or losing traction.

Final Assessment

The $490 central target for UNH is the average of nine verified analyst price targets ranging from $438 to $531, and it sits roughly 19% above the latest verified price near $410.91. Reaching it would require the margin-recovery story to keep delivering — sustained MLR improvement, continued guidance increases, and durable Optum growth — while avoiding fresh regulatory or legal setbacks. The wide analyst range and a handful of recently lowered targets underscore that the outcome is far from certain. Investors should watch earnings, Medicare Advantage policy, the Department of Justice investigation, and analyst revisions before drawing conclusions about whether the target is achievable.

Exploring AI Daily Buy/Sell Signals for UNH

In my own analysis, I frequently turn to Tickeron’s AI Daily Buy/Sell Signals to stay on top of shifting conditions in stocks like UNH. These signals draw on artificial intelligence to scan thousands of securities in real time, combining technical patterns and market data to highlight potential entry or exit points. For healthcare names in particular, the tool helps cut through noise and focus on actionable changes as earnings, costs, and policy developments unfold.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: UNH

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


UNH's RSI Oscillator is staying in oversold zone for 2 days

It is expected that a price bounce should occur soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a +1.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where UNH advanced for three days, in 187 of 331 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.

UNH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on UNH as a result. In 56 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 67%.

The Moving Average Convergence Divergence Histogram (MACD) for UNH turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 27 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 59%.

UNH moved below its 50-day moving average on November 17, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for UNH crossed bearishly below the 50-day moving average on November 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 67%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where UNH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 52%.

The Aroon Indicator for UNH entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 58 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. UNH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.594) is normal, around the industry mean (3.520). P/E Ratio (25.266) is within average values for comparable stocks, (126.353). Projected Growth (PEG Ratio) (1.025) is also within normal values, averaging (0.786). UNH has a moderately high Dividend Yield (0.024) as compared to the industry average of (0.009). P/S Ratio (0.757) is also within normal values, averaging (0.569).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. UNH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.

Notable companies

The most notable companies in this group are Unitedhealth Group (NYSE:UNH), CVS HEALTH Corp (NYSE:CVS), Elevance Health (NYSE:ELV), Cigna Group (The) (NYSE:CI), Humana (NYSE:HUM), Centene Corp (NYSE:CNC).

Industry description

Managed healthcare industry focuses on providing health/medical and disability insurance plans, generally intended to reduce the cost of for-profit health care. The insurance products might be provided through employer-paid (fully or partly) insurance and benefit programs, or through Medicare/Medicaid. Some of the largest providers of managed health care include Aetna, Humana Inc., and Cigna, and UnitedHealthcare.

Market Cap

The average market capitalization across the Managed Health Care Industry is 67.69B. The market cap for tickers in the group ranges from 335.99K to 353.79B. UNH holds the highest valuation in this group at 353.79B. The lowest valued company is IHGP at 335.99K.

High and low price notable news

The average weekly price growth across all stocks in the Managed Health Care Industry was -12%. For the same Industry, the average monthly price growth was -11%, and the average quarterly price growth was 1%. PGNY experienced the highest price growth at -1%, while CLOV experienced the biggest fall at -25%.

Volume

The average weekly volume growth across all stocks in the Managed Health Care Industry was 80%. For the same stocks of the Industry, the average monthly volume growth was 91% and the average quarterly volume growth was 67%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 61
P/E Growth Rating: 44
Price Growth Rating: 54
SMR Rating: 72
Profit Risk Rating: 91
Seasonality Score: -6 (-100 ... +100)
AI Robots 7
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of hospital and medical service plans

Industry ManagedHealthCare

Industry
Managed Health Care
Address
1 Health Drive
Phone
+1 800 328-5979
Employees
390000
Web
https://www.unitedhealthgroup.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.